Springer Nature has integrated its AdisInsight platform into Anthropic’s Claude, enabling institutional subscribers to access curated pharmaceutical intelligence directly within the Claude interface.
AdisInsight provides evidence‑linked data covering drug development, clinical trials, adverse drug reaction case reports, regulatory milestones such as drug approvals, and updates on mergers, acquisitions, and licensing opportunities. The integration is delivered via a secure Model Context Protocol (MCP) server and Claude Connectors, allowing Claude to retrieve licensed AdisInsight content in real time while maintaining provenance, access controls, and usage tracking.
According to Springer Nature, the initiative reflects its broader commitment to ensuring that trusted content remains visible and measurable in AI‑enabled environments. Saskia Steinacker, Chief Product Officer, indicated that the partnership aligns with the publisher’s approach of offering customers greater flexibility in how they access and use content. She noted that it builds on ongoing efforts to enable responsible access to high‑quality research material while ensuring usage can be tracked.
Harald Wirsching, Executive Vice President for Data and Analytics Solutions, emphasized that the integration allows users to access Springer Nature’s trusted data without leaving their existing workflows. He explained that embedding AdisInsight within AI‑driven environments supports seamless use of information across life sciences workflows, enabling faster interrogation of data and more confident application in research, regulatory, and business decision‑making contexts.
Users can continue to access AdisInsight through its web interface, the AskAdis conversational search tool, Springer Nature’s generative AI assistant, or via APIs that connect data into internal systems and AI environments. The Claude integration adds another option within this flexible access model.
Earlier in 2026, Springer Nature introduced ARC3, a framework designed to provide corporate customers with responsible and legal access to its content for integration into AI‑powered products and workflows. This framework supports both internal R&D applications and external AI development.
The publisher continues to pursue a researcher‑led approach to AI, focusing on enabling access to trusted content within the workflows researchers use. It is selectively developing AI tools for publishing processes and exploring partnerships aligned with its AI principles to support research discovery, decision‑making, and engagement. Springer Nature also engages actively with the research community to address evolving needs and contribute to industry discussions and policies around AI.
Further details on its AI strategy are available in the publisher’s latest annual report and on its AI hub.
Click here to read the original press release.
